StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Sunday morning. The brokerage issued a sell rating on the stock. OCX has been the subject of a number of other reports. Needham & Company LLC dropped their price objective on OncoCyte from $4.25 to $3.60 and set a […]
Equities research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued on Monday. The firm set a “sell” rating on the stock. A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC reduced their price target on […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the stock. Other research analysts have also issued reports about the stock. Benchmark decreased their price objective on shares of OncoCyte from $9.00 to $5.00 and set a speculative buy rating […]
OncoCyte (NASDAQ:OCX – Get Free Report) had its price objective lowered by investment analysts at Piper Sandler from $3.50 to $3.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s target price suggests a potential downside of 10.18% from […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock. Several other research firms also recently weighed in on OCX. Benchmark decreased their price target on shares of OncoCyte from $9.00 to $5.00 and set a speculative buy […]